Top Markets
Coin of the day
Cortexyme, Inc. Cortexyme, Inc.

Cortexyme, Inc.

CRTX
Clasificación en acciones #25185
Cortexyme, Inc. is a clinical-stage biopharmaceutical firm committed to... Cortexyme, Inc. is a clinical-stage biopharmaceutical firm committed to pioneering new therapies for Alzheimer's and various other degenerative conditions. The company's primary investigational drug, atuzaginstat (also known as COR388), is an orally delivered, small molecule inhibitor engineered to cross the blood-brain barrier and target gingipain. This compound is currently in Phase II/III clinical trials, where it is being assessed for its potential use in individuals with mild to moderate Alzheimer's disease, as well as for tackling oral squamous cell carcinoma, periodontitis, and coronavirus infections. Established in 2012, Cortexyme, Inc. is headquartered in South San Francisco, California.
Precio por acción
$1.95
Última sincronización: 2022-07-29
Capitalización bursátil
$52.48M
Cambio (1 día)
2.63%
Cambio (1 año)
0.00%
País
US
Comercio Cortexyme, Inc. (CRTX)

Categoría

Historial del precio de la acción de Cortexyme, Inc. (CRTX)
Precio más alto de cierre: $2.18 el 2022-07-01

Precio más bajo de cierre: $26.37 el 2019-05-01
Historial del precio de la acción de Cortexyme, Inc. desde 2019 hasta 2026
Desempeño anual del precio de la acción
Año Rendimiento
2022 -82.87%
2021 -62.60%
2020 -23.16%
2019 0.00%
Precio de la acción de empresas similares o competidoras
Empresa Precio de la acción Cambio 1a% País
$539.14 35.65%
US
$1.04K 56.21%
NL
$118.70 -18.24%
AU
$760.57 8.46%
CH
$130.43 397.46%
US